

# Zuzana Walker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123383/publications.pdf>

Version: 2024-02-01

139  
papers

11,618  
citations

34105

52  
h-index

29157

104  
g-index

144  
all docs

144  
docs citations

144  
times ranked

10417  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
2	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	10.2	598
3	Lewy body dementias. <i>Lancet</i> , The, 2015, 386, 1683-1697.	13.7	422
4	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology</i> , The, 2009, 8, 613-618.	10.2	420
5	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.1	365
6	Depression in older adults. <i>BMJ: British Medical Journal</i> , 2011, 343, d5219-d5219.	2.3	299
7	EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 443-450.	6.4	263
8	Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1176-1181.	1.9	250
9	Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 134-140.	1.9	239
10	Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. <i>JAMA Neurology</i> , 2015, 72, 287.	9.0	238
11	Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. <i>Neuropsychopharmacology</i> , 2013, 38, 938-949.	5.4	202
12	Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. <i>International Psychogeriatrics</i> , 2009, 21, 813.	1.0	188
13	Islington study of dementia subtypes in the community. <i>British Journal of Psychiatry</i> , 2002, 180, 270-276.	2.8	185
14	START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia. <i>Health Technology Assessment</i> , 2014, 18, 1-242.	2.8	156
15	Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial. <i>International Psychogeriatrics</i> , 2001, 13, 199-205.	1.0	155
16	Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial. <i>BMJ</i> , The, 2013, 347, f6276-f6276.	6.0	154
17	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	3.3	153
18	Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. <i>Neurology</i> , 2004, 62, 1568-1572.	1.1	143

#	ARTICLE	IF	CITATIONS
19	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain, 2018, 141, 2740-2754.	7.6	143
20	Diagnostic accuracy of <sup>123</sup> I-FP-CIT SPECT in possible dementia with Lewy bodies. British Journal of Psychiatry, 2009, 194, 34-39.	2.8	135
21	Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International Journal of Geriatric Psychiatry, 2000, 15, 387-392.	2.7	129
22	Olanzapine in dementia with Lewy bodies: a clinical study. International Journal of Geriatric Psychiatry, 1999, 14, 459-466.	2.7	121
23	Abuse of people with dementia by family carers: representative cross sectional survey. BMJ: British Medical Journal, 2009, 338, b155-b155.	2.3	119
24	Autopsy validation of <sup>123</sup> I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 88, 276-283.	1.1	118
25	The determinants of family carers' abusive behaviour to people with dementia: Results of the CARD study. Journal of Affective Disorders, 2010, 121, 136-142.	4.1	107
26	Neuropsychological performance in Lewy body dementia and Alzheimer's disease. British Journal of Psychiatry, 1997, 170, 156-158.	2.8	98
27	Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 717-728.	2.6	94
28	Long-term outcome of depressive pseudodementia in the elderly. Journal of Affective Disorders, 2007, 101, 123-129.	4.1	88
29	Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1063-1070.	1.9	88
30	Violent Incidents in a Psychiatric Intensive Care Unit. British Journal of Psychiatry, 1994, 164, 826-828.	2.8	87
31	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	6.4	86
32	The functional anatomy of divided attention in amnesic mild cognitive impairment. Brain, 2005, 128, 1418-1427.	7.6	83
33	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	6.4	81
34	What to tell dementia caregivers – the rule of threes. International Journal of Geriatric Psychiatry, 2003, 18, 313-317.	2.7	77
35	Dementia diagnostic criteria in Down syndrome. International Journal of Geriatric Psychiatry, 2015, 30, 857-863.	2.7	77
36	Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Movement Disorders, 2009, 24, S754-9.	3.9	75

#	ARTICLE	IF	CITATIONS
37	Use of Flutemetamol F 18â€“Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. JAMA Neurology, 2018, 75, 1114.	9.0	75
38	Subjective cognitive impairment: Functional MRI during a divided attention task. European Psychiatry, 2011, 26, 457-462.	0.2	74
39	In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet, The, 1999, 354, 646-647.	13.7	73
40	Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. International Journal of Geriatric Psychiatry, 2009, 24, 865-874.	2.7	73
41	Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet, The, 1995, 346, 185.	13.7	69
42	Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica, 2004, 109, 140-146.	4.5	69
43	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. Journal of Alzheimer's Disease, 2017, 57, 787-795.	2.6	69
44	Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial. Lancet Psychiatry,the, 2014, 1, 539-548.	7.4	68
45	Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrategies for RelaTives) study): a pragmatic randomised controlled trial. BMJ, The, 2013, 347, f6342-f6342.	6.0	67
46	Family carers' distress and abusive behaviour: longitudinal study. British Journal of Psychiatry, 2010, 196, 480-485.	2.8	65
47	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	6.4	61
48	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.8	60
49	Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2000, 15, 267-273.	2.7	59
50	Performance of [ <sup>18</sup> F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIAâ€“AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 25-34.	2.4	57
51	EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 434-442.	6.4	56
52	Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 609-614.	2.1	55
53	Relationship of exercise and other risk factors to depression of Alzheimer's disease: the LASER-AD study. International Journal of Geriatric Psychiatry, 2005, 20, 261-268.	2.7	53
54	Oxidative stress and cognitive ability in adults with Down syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 76-80.	4.8	52

#	ARTICLE	IF	CITATIONS
55	A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairmentâ€“ThinkingFit: pilot and feasibility study for a randomized controlled trial. BMC Psychiatry, 2014, 14, 129.	2.6	52
56	Clinical usefulness of dopamine transporter SPECT imaging with <sup>123</sup> I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. British Journal of Psychiatry, 2015, 206, 145-152.	2.8	52
57	Prodromal Dementia with Lewy Bodies and Prodromal Alzheimerâ€™s Disease: A Comparison of the Cognitive and Clinical Profiles. Journal of Alzheimer's Disease, 2017, 58, 463-470.	2.6	48
58	The Effect of Mindfulness-based Programs on Cognitive Function in Adults: A Systematic Review and Meta-analysis. Neuropsychology Review, 2022, 32, 677-702.	4.9	48
59	An fMRI study of verbal episodic memory encoding in amnesic mild cognitive impairment. Cortex, 2008, 44, 869-880.	2.4	47
60	Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study. Journal of Alzheimer's Disease, 2012, 31, 277-283.	2.6	42
61	Efficacy of lifestyle and psychosocial interventions in reducing cognitive decline in older people: Systematic review. Ageing Research Reviews, 2020, 62, 101113.	10.9	42
62	Antidepressant Treatment of Chronic Tension-Type Headache: A Comparison Between Fluoxetine and Desipramine. Headache, 1998, 38, 523-528.	3.9	41
63	Clinical use of structural magnetic resonance imaging in the diagnosis of dementia in adults with Down's syndrome. Irish Journal of Psychological Medicine, 2002, 19, 60-63.	1.0	41
64	Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging. Movement Disorders, 2003, 18, S34-S38.	3.9	41
65	Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature. International Psychogeriatrics, 2014, 26, 1945-1953.	1.0	40
66	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
67	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open, 2014, 4, e005122-e005122.	1.9	35
68	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	6.4	35
69	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	6.4	35
70	<sup>11</sup> C-PIB PET in subjective cognitive impairment. European Psychiatry, 2010, 25, 123-125.	0.2	34
71	Factors that predict cognitive decline in patients with subjective cognitive impairment. International Psychogeriatrics, 2015, 27, 1671-1677.	1.0	33
72	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open, 2012, 2, e000380.	1.9	31

#	ARTICLE	IF	CITATIONS
73	Vitamins, Trace Elements, and Antioxidant Status in Dementia Disorders. <i>International Psychogeriatrics</i> , 2001, 13, 265-275.	1.0	29
74	Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 158-164.	1.9	29
75	Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. <i>British Journal of Psychiatry</i> , 2018, 212, 155-160.	2.8	28
76	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1526-1533.	6.4	28
77	Clinical effectiveness of the START (STrategies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial. <i>British Journal of Psychiatry</i> , 2020, 216, 35-42.	2.8	27
78	The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 737-745.	3.7	26
79	A memory clinic for older people with intellectual disabilities. <i>Aging and Mental Health</i> , 2003, 7, 418-423.	2.8	24
80	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1546-1556.	6.4	24
81	Secrets and lies: the dilemma of disclosing the diagnosis to an adult with dementia. <i>Age and Ageing</i> , 2003, 32, 439-441.	1.6	23
82	Exploring the experiences of people with mild cognitive impairment and their caregivers with particular reference to healthcare – a qualitative study. <i>International Psychogeriatrics</i> , 2014, 26, 475-485.	1.0	23
83	Endogenous Antioxidant Activities in Relation to Concurrent Vitamins A, C, and E Intake in Dementia. <i>International Psychogeriatrics</i> , 2002, 14, 7-15.	1.0	20
84	Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). <i>Journal of Nuclear Medicine</i> , 2014, 55, 1281-1287.	5.0	19
85	A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015, 16, 316-322.	2.5	19
86	Data quality, floor and ceiling effects, and test&ndash;retest reliability of the Mild Cognitive Impairment Questionnaire. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 43-47.	1.2	19
87	Prediction of survival in Alzheimer's disease&mdash;The LASER&mdash;AD longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 739-747.	2.7	18
88	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 341-350.	8.8	18
89	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. <i>PLoS ONE</i> , 2014, 9, e97709.	2.5	17
90	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using <sup>123</sup> I-Ioflupane Injection (DaTscan) Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1288-1296.	5.0	17

#	ARTICLE	IF	CITATIONS
91	Attitudes to depression in hospital inpatients: A comparison between older and younger subjects. <i>Aging and Mental Health</i> , 1998, 2, 36-39.	2.8	16
92	Ten years of cholinesterase inhibitors. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 437-442.	2.7	16
93	Memory Complaints with and without Memory Impairment: The Impact of Leukoaraiosis on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1104-1112.	1.8	16
94	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.1	14
95	Psychiatric morbidity in elderly attenders at an accident and emergency department. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 951-957.	2.7	13
96	Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1122-1125.	6.4	13
97	Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?. <i>International Psychogeriatrics</i> , 2013, 25, 120-127.	1.0	13
98	The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment. <i>International Psychogeriatrics</i> , 2014, 26, 487-497.	1.0	13
99	APPLEtree (Active Prevention in People at risk of dementia: Lifestyle, bEhaviour change and Technology) Tj ETQq1 1 0.784314 rgBT Psychiatry, 2020, 35, 811-819.	2.7	13
100	<sup>123</sup> I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 662-667.	1.9	13
101	Imaging in neurodegenerative disorders: recent studies. <i>Current Opinion in Psychiatry</i> , 2005, 18, 640-646.	6.3	12
102	Falling through the cracks: Stakeholders' views around the concept and diagnosis of mild cognitive impairment and their understanding of dementia prevention. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1349-1357.	2.7	12
103	The Mini-SIB: a short scale for measuring cognitive function in severe dementia. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1001-1002.	2.7	10
104	Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. <i>International Psychogeriatrics</i> , 2013, 25, 286-291.	1.0	10
105	Dementia with Lewy Bodies: Clinical Characteristics and Diagnostic Criteria. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 188-194.	2.3	9
106	Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. <i>International Psychogeriatrics</i> , 2005, 17, 91-98.	1.0	9
107	Dopaminergic imaging: clinical utility now and in the future. <i>International Psychogeriatrics</i> , 2011, 23, S32-S40.	1.0	9
108	In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and in Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 46-51.	1.5	8



#	ARTICLE	IF	CITATIONS
109	Magnetic Resonance Imaging in Stable Mild Cognitive Impairment, Prodromal Alzheimer's Disease, and Prodromal Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 583-588.	1.5	8
110	Trends in referred patient profiles in a memory clinic over 20 years. <i>Dementia</i> , 2016, 15, 789-797.	2.0	7
111	Author response: Autopsy validation of <sup>123</sup> I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. <i>Neurology</i> , 2017, 89, 751-751.	1.1	6
112	[ <sup>123</sup> I]N-(2-fluoropropyl-2-carbomethoxy-4-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2012, 8, 74-83.	0.8	5
113	Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12135.	2.4	5
114	The effect of remotely delivered lifestyle interventions on cognition in older adults without dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 72, 101505.	10.9	5
115	Dietary and endogenous antioxidants in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 639-641.	2.7	3
116	Dementia with Lewy bodies. <i>British Journal of Neuroscience Nursing</i> , 2015, 11, 146-149.	0.2	3
117	Dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 310-311.	1.1	3
118	Letter to the editor. <i>Journal of Intellectual Disability Research</i> , 2004, 48, 769-770.	2.0	2
119	The Development and Validation of a Quality of Life Measure for People with Mild Cognitive Impairment (The MCQ). <i>Value in Health</i> , 2013, 16, A550.	0.3	2
120	Lewy Body Dementias. <i>Focus</i> (American Psychiatric Publishing), 2017, 15, 85-100.	0.8	2
121	Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 609-614.	6.4	2
122	SPECT/PET Findings in Lewy Body Dementia. , 2014, , 373-415.		2
123	Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
124	Cardiopulmonary resuscitation and other life supporting measures in elderly patients: Attitudes of psychiatrists and geriatricians. <i>Aging and Mental Health</i> , 1999, 3, 336-339.	2.8	1
125	Long-term outcome of depressive pseudodementia in the elderly. <i>European Psychiatry</i> , 2007, 22, S25.	0.2	1
126	The effect of a mindfulness-based versus health self-management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCD-Well randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1



#	ARTICLE	IF	CITATIONS
127	Self-reflection is associated with markers of Alzheimer's disease in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
128	Laterality in Parkinson's disease and susceptibility to psychosis. <i>Schizophrenia Research</i> , 1997, 24, 22.	2.0	0
129	Neuroimaging and the Psychiatry of Late Life Edited by David Ames & Edmond Chiu. Cambridge: Cambridge University Press. 1997. 226 pp. £60.00 (US\$95.00) (hb). ISBN 0-521-49505-9. <i>British Journal of Psychiatry</i> , 1999, 175, 296-296.	2.8	0
130	Six years experience with acetylcholinesterase inhibitors in a clinical setting. <i>European Psychiatry</i> , 2007, 22, S305.	0.2	0
131	624 " Association of apathy with caregiver burden in amnesic mild cognitive impairment. <i>European Psychiatry</i> , 2013, 28, 1.	0.2	0
132	O4-06-03: PREVALENCE OF DLB FEATURES IN POSSIBLE DEMENTIA WITH LEWY BODIES AND ITS RELATIONSHIP TO CHANGES IN DEMENTIA DIAGNOSTIC CATEGORY AFTER DOPAMINE TRANSPORTER IMAGING USING DATSCAN, . , 2014, 10, P262-P262.		0
133	Authors' reply. <i>British Journal of Psychiatry</i> , 2015, 207, 364-365.	2.8	0
134	Dopamine Transporter Imaging. , 2017, , 141-155.		0
135	Author's reply to: Difficulties of diagnosing and managing dementia in people with Down syndrome. <i>British Journal of Psychiatry</i> , 2018, 213, 669-669.	2.8	0
136	Author's reply. <i>British Journal of Psychiatry</i> , 2018, 213, 667-668.	2.8	0
137	Dementia with Lewy Bodies. , 2019, , 88-100.		0
138	SPECT/PET Findings in Dementia with Lewy Bodies. , 2021, , 515-561.		0
139	Olanzapine in dementia with Lewy bodies: a clinical study. <i>International Journal of Geriatric Psychiatry</i> , 1999, 14, 459-466.	2.7	0